Skip to content
Iodamide meglumine
Renovue (iodamide meglumine) is a small molecule pharmaceutical. Iodamide meglumine was first approved as Renovue-65 on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Iodamide meglumine
Tradename
Company
Number
Date
Products
RENOVUE-65Bracco DiagnosticsN-017902 DISCN1982-01-01
1 products
RENOVUE-DIPBracco DiagnosticsN-017903 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIODAMIDE MEGLUMINE
INN—
Description
Renovue (iodamide meglumine) is a small molecule pharmaceutical. Iodamide meglumine was first approved as Renovue-65 on 1982-01-01.
Classification
Small molecule
Drug classiodine-containing contrast media
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)NCc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Identifiers
PDB—
CAS-ID18656-21-8
RxCUI—
ChEMBL IDCHEMBL1201172
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 0 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
14 adverse events reported
View more details